---
title: "Longshenrongfa Pharmaceutical Industry: The holding subsidiary Guofang Testing has obtained the CNAS laboratory accreditation certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243585452.md"
description: "Longshenrongfa Pharmaceutical Industry announced that its holding subsidiary Gansu Pharmaceutical Group Guofang Testing Co., Ltd. recently received the laboratory accreditation certificate awarded by the China National Accreditation Service for Conformity Assessment (CNAS). The acquisition of the CNAS laboratory accreditation certificate indicates that the management and technical capabilities of Guofang Testing Laboratory have been recognized at both national and international levels, which will have a positive impact on the company's future operations. The acquisition of this certificate will not have a significant impact on the company's current operating performance"
datetime: "2025-06-08T08:23:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243585452.md)
  - [en](https://longbridge.com/en/news/243585452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243585452.md)
generator: "portal-rs"
---

# Longshenrongfa Pharmaceutical Industry: The holding subsidiary Guofang Testing has obtained the CNAS laboratory accreditation certificate

Longshenrongfa Pharmaceutical Industry announced that its holding subsidiary, Gansu Pharmaceutical Group Guofang Testing Co., Ltd., recently received the laboratory accreditation certificate awarded by the China National Accreditation Service for Conformity Assessment (CNAS). The acquisition of the CNAS laboratory accreditation certificate indicates that the management and technical capabilities of Guofang Testing Laboratory have been recognized at both national and international levels, which will have a positive impact on the company's future operations. The acquisition of this certificate will not have a significant impact on the company's current operating performance

### Related Stocks

- [300534.CN](https://longbridge.com/en/quote/300534.CN.md)

## Related News & Research

- [RLO: Tripling revenue ambition, global defence focus, and innovation drive long-term growth](https://longbridge.com/en/news/297759336.md)
- [First National of Nebraska to buy InBankshares in cash deal valued at $200-$204 million](https://longbridge.com/en/news/297790606.md)
- [Cupid share price in focus on board approval to set up manufacturing venture in South African](https://longbridge.com/en/news/297455298.md)
- [ANOT: Q2 2026 sales surged 64% year-over-year, but losses and liquidity risks persist](https://longbridge.com/en/news/297550756.md)
- [Shoprite guides FY2027 trading margin to hold at 6% on 53-week basis](https://longbridge.com/en/news/297604039.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**